Director, Experimental Interventional Cardiology
CVI Program Unit(s):
Lipid / Atherosclerosis / CAD / ACS / Prevention
CVI Research Description:
I have a large animal laboratory dedicated to evaluation of new devices and treatment of atherosclerosis and myocardial infarction. Over the past years the laboratory has been interested in diabetic vasculopathy, pharmacologic and device treatment of coronary and peripheral atherosclerosis and stem cell treatment of myocardial infarction.
Clinically, I also have research interests involving identification of high risk coronary lesions and treatment and identification of patients with increased risk of future ischemic events.
Schaar JA, Muller JE, Falk E, Virmani R, Fuster V,Serruys PW, Colombo A, Stefanadis C, Casscells W, Moreno PR, Maseri A, van der Steen AFW: Terminology for high-risk and vulnerable coronary artery plaques. European Heart Journal 25: 1-6, 2004.
Laskey WK, Selzer F, Cohen H, Holmes D, Wilensky R, Williams D, Detre K: Temporal variation in fatal percutaneous coronary intervention outcomes: A report from the NHLBI Dynamic Registry. Am Heart J 150: 569, 2005.
Hirshfeld JW, Wilensky RL: Drug eluting stents are here - now what? Implications for clinical practice and health care costs. Cleveland Clinic Journal. In Press, 2004.
Naimark WA, Lepore JJ, Klugherz BD, Wang Z, Guy TS, Osman H, Moainie SL, Gorman RC, Gorman JH III, Palasis M, Parmacek MS, Wilensky RL. : Adenovirus-catheter compatibility increases gene expression. Hum Gene Ther 14: 161-167, 2003.
Mainigi SK, Goldberg LR, Sasseen BM, See VY, Wilensky RL. : Relative contributions of intimal hyperplasia and vascular remodeling in early cardiac transplant mediated coronary artery disease. Am J. Cardiol 91: 293-296, 2003.
Meneveau NF, Klugherz BD, Chaquor B, Golden M, Jouille MM, Macarak E, Weisz PB, Wilensky RL. : Separate and combined effects of local and continuous intravenous administration and beta-cyclodextrin tetradecasulfate on intimal hyperplasia after angioplasty in porcine coronary arteries. J Cardiovasc Pharmacol Therapeut 8: 53-60, 2003.
See VY, DeNofrio D, Goldberg L, Chang G, Sasseen B, Kolansky DM, Pickering F, Kao A, Loh E, Wilensky RL. : Effect of atorvastatin on post-cardiac transplant increase in low-density lipoprotein and cholesterol levels reduces development of intimal hyperplasia and ameliorates progression of endothelial dysfunction. Am J Cardiol 92: 11-15, 2003.
Perlstein I, Connolly JM, Cui X, Song C, Quanyi Li, Jones PL, Lu Z, DeFelice S, Klugherz B, Wilensky R, Levy RJ. : DNA Delivery from an intravascular stent with a denatured collagen-polylactic-polyglycolic acid controlled release coating: mechanisms of enhanced transfection, in press. Gene Therapy 2003.
Kizer JR, Muttreja MR, Matthei WH, McConnell J, Nardone H, Sonel AF, Keane MG, Wilensky RL. : Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention, in press. Eur Heart J 2003.
Wilensky RL, Klugherz BD. : Coronary artery disease and congestive heart failure. A Clinician’s guide to ambulatory diagnosis and treatment. Heart Failure. Jessup M, Loh E (eds.). Humana Press, Totowa Page: 131-148, 2003.
back to top
Last updated: 04/28/2015
The Trustees of the University of Pennsylvania